Clinical Trials Logo

Clinical Trial Summary

Background:

- An acquired heart disease is one that a person gets after they are born. Two of these are rheumatic heart disease (RHD) and endomyocardial fibrosis (EMF). They are found more commonly in people who live in Africa than in other places in the world. Researchers want to learn more about these diseases. They especially want to know what role genes and other factors play in them.

Objective:

- To identify genetic risk factors for RHD and EMF in sub-Saharan Africa.

Eligibility:

- Children and adults with RHD or EMF.

- Healthy volunteers over age 10.

Design:

- Participants will come from existing study groups in Uganda and Nigeria.

- Participants may be required to provide a sample of their DNA. They will do this with either a blood or saliva sample or a swab of the mouth.

- Collected samples will be labeled with a code and sent to a lab in the United States for analysis. Remaining portions of participants samples will be stored for an unlimited period of time. They may be used in future studies.

- Some genetic and health information from participants might be placed into one or more scientific databases.

- Participant names and identifying information will be kept private. But there is a small chance someone could trace them from their genetic information.


Clinical Trial Description

Recent advances in genomic techniques are making possible a new wave of genetic discovery in many complex diseases. However, the genetic risk factors for two forms of acquired heart disease that are particularly common in Africa - rheumatic heart disease (RHD) and endomyocardial fibrosis (EMF) remains unknown. In this application, we propose to evaluate genetic risk factors for rheumatic heart disease (RHD) and endomyocardial fibrosis (EMF). A number of factors should facilitate the identification of genetic risk variants underlying the two conditions. First, both forms of acquired heart disease are endemic to sub-Saharan Africa (SSA). Second, affected patients and those who do not develop the conditions share a common environment. Finally, the availability of high density SNP arrays to capture common and rare variation makes the characterization of genomic variation better than ever. Patients will be enrolled at the Uganda Heart Institute in Kampala, Uganda, and at the College of Medicine, University of Lagos, Nigeria, with the potential to include other African sites. Genomic studies will be done at the NIH. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02124109
Study type Observational
Source National Institutes of Health Clinical Center (CC)
Contact
Status Completed
Phase
Start date April 3, 2014
Completion date February 6, 2020

See also
  Status Clinical Trial Phase
Recruiting NCT05991219 - Screening and Secondary Prevention Rheumatic Heart Disease Study
Completed NCT02661763 - Rheumatic Heart Disease Study in Lusaka N/A
Completed NCT02188862 - Genetic Susceptibility to Rheumatic Heart Disease in the Pacific Region N/A
Completed NCT01178710 - Effect of Simvastatin on Cardiac Function N/A
Recruiting NCT05693545 - GOALIE: Intramuscular vs. Enteral Penicillin Prophylaxis to Prevent Progression of Latent RHD Trial Phase 2
Terminated NCT03926156 - RIvoraxaban in Mitral Stenosis Phase 3
Not yet recruiting NCT06150274 - Comparison of Wire Assisted Percutaneous Balloon Mitral Valvulotomy With Standard Inoue Balloon Valvulotomy N/A
Recruiting NCT05783375 - Accelerating Delivery of rheUmatic Heart Disease Preventive iNterventions in Northern Uganda N/A
Completed NCT02474108 - Surgical Prevention of Atrial Fibrillation in Patients With Rheumatic Mitral Valve Lesion and Left Atrium Enlargement N/A
Recruiting NCT04556188 - The Clinical Influence of Developing a Sustainable Cardiac Surgery Service to Reduce the Burden of Rheumatic Heart Disease in Sub-Saharan Africa
Recruiting NCT03991910 - The Effect of Ramipril in Suppressing ST2 Expression in Rheumatic Mitral Stenosis Patients Phase 3
Active, not recruiting NCT03346525 - Determining the Impact of Penicillin in Latent RHD: The GOAL Trial Phase 2
Recruiting NCT05504928 - Effectiveness of a School-centered Prevention Program on Prevalence of Latent Rheumatic Heart Disease N/A
Not yet recruiting NCT03549052 - Right Ventricular Echo Assessment in Mitral Valve Replacement
Recruiting NCT05487469 - Thymosin α1 Use in Rheumatic Heart Disease Patients Undergoing Cardiac Surgery on Cardiopulmonary Bypass N/A
Active, not recruiting NCT05276999 - Rheumatic Heart Disease Community Streptococcal Treatment Program "RESET" N/A
Completed NCT05668611 - Train the Trainer Curriculum to Scale up AI Supported Echo for RHD Screening in a Public Health System N/A
Active, not recruiting NCT05211024 - A Long-term Follow up Study for Patients Who Participated in the GOAL Trial (GOAL-Post)
Withdrawn NCT02832531 - INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Superiority Phase 3
Completed NCT01794884 - Validity Study of Glutamine to Improve Cardiac Function in Cardiac Surgery Phase 2